1 / 9

Simeprevir in Treatment –Experienced Genotype 1 ASPIRE Trial

Explore results of Simeprevir treatment in ASPIRE Trial for HCV Genotype 1 patients, efficacy at different doses and response rates. Learn about drug dosing and conclusions. Slide deck from University of Washington’s Hepatitis C Online and Hepatitis Web Study.

kgibson
Download Presentation

Simeprevir in Treatment –Experienced Genotype 1 ASPIRE Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentExperienced Simeprevir in Treatment –Experienced Genotype 1 ASPIRE Trial Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  2. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Features Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  3. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Design Week 0 12 24 48 72 Simeprevir 100 mg Placebo n = 66 Peginterferon+ Ribavirin Simeprevir 150 mg Placebo n =66 Peginterferon+ Ribavirin Simeprevir 100 mg Placebo n =65 Peginterferon+ Ribavirin Simeprevir 150 mg Placebo n =68 Peginterferon+ Ribavirin Simeprevir 100 mg n = 66 Peginterferon+ Ribavirin Simeprevir 150 mg n =65 Peginterferon+ Ribavirin Placebo n = 66 Peginterferon+ Ribavirin Drug Dosing: Simeprevir: 100 or 150 mg once daily; Peginterferon alfa-2a (PEG): 180 mcg/week Ribavirin (RBV) weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  4. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Results Week 0 12 24 48 72 Simeprevir 100 mg Placebo n = 66 SVR 24 = 70% Peginterferon+ Ribavirin Simeprevir 150 mg Placebo n =66 SVR 24 = 62% Peginterferon+ Ribavirin Simeprevir 100 mg Placebo n =65 SVR 24 = 66% Peginterferon+ Ribavirin Simeprevir 150 mg Placebo n =68 SVR 24 = 72% Peginterferon+ Ribavirin Simeprevir 100 mg n =66 SVR 24 = 61% Peginterferon+ Ribavirin Simeprevir 150 mg n =65 SVR 24 = 80% Peginterferon+ Ribavirin Placebo SVR 24 = 23% n = 66 Peginterferon+ Ribavirin Drug Dosing: Simeprevir: 100 or 150 mg once daily; Peginterferon alfa-2a (PEG): 180 mcg/week Ribavirin (RBV) weight-based (in 2 divided doses): 1000 mg if < 75kg or 1200 mg/day if ≥ 75kg Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  5. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Results ASPIRE: SVR 24, by Treatment Regimen 46/66 43/65 40/66 44/66 49/68 52/65 15/66 Simeprevir 100 mg Simeprevir 150 mg Placebo Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  6. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Results ASPIRE: SVR 24, by Prior Treatment Response 46/66 43/65 40/66 44/66 49/68 52/65 15/66 Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  7. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Results ASPIRE: SVR 24, by Prior Treatment Response and GT 1 Subtype 46/66 43/65 40/66 44/66 49/68 52/65 15/66 Relapser Partial Responder Null Responder Source: Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  8. Simeprevir in Treatment Experienced Genotype 1 HCVASPIRE Trial: Conclusions Source:Zeuzem S, et al. Gastroenterol. 2014;146:430-41.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related